Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161675 · ClinicalTrials.gov registry record · NA
Feasibility of Delivering VergeRx at FQHCs
A NA study of Tobacco Use Cessation, sponsored by University of Virginia.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06161675 is a NA study of Tobacco Use Cessation that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 100 participants, below the 882-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06161675, a NA study of Tobacco Use Cessation, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which generally provide healthcare services to low income and Medicaid insured patients, are more likely to serve individuals who use tobacco and are required to report tobacco use screening rates and their delivery of cessation interventions. Thus, FQHCs are an ideal community-partner to reach low-income smokers, particularly smokers who are not currently seeking treatment. To address this gap, the investigators developed a pharmacist-delivered smoking cessation intervention to help facilitate nicotine replacement therapy medication adherence among smokers. The proposed study aims to examine the feasibility of delivering the pharmacist-delivered smoking cessation intervention to FQHC patients who are ready to quit, and expanding the intervention for smokers not ready to quit by adding 2 pre-quit sessions focused on rate reduction. The investigators will also determine facilitators and barriers to adopting and implementing the program in FQHCs.
Conditions Studied
Interventions
- BEHAVIORAL QuitAid
- DRUG Nicotine lozenge
- BEHAVIORAL SmokefreeTXT
- DRUG Nicotine Replacement Therapy Patch
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161675
The ClinicalTrials.gov registry entry for NCT06161675 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 882-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (89% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 4 interventions - of which QuitAid is the first listed.
NCT06161675 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06161675 about?
NCT06161675 is a clinical study titled "Feasibility of Delivering VergeRx at FQHCs". Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which...
What is the current status of trial NCT06161675?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-09-23. Estimated completion is 2026-07-01.
What conditions does trial NCT06161675 study?
This clinical trial studies the following conditions: Tobacco Use Cessation.
What interventions are being tested in trial NCT06161675?
The interventions under investigation include: QuitAid (BEHAVIORAL), Nicotine lozenge (DRUG), SmokefreeTXT (BEHAVIORAL), Nicotine Replacement Therapy Patch (DRUG).
Who is sponsoring clinical trial NCT06161675?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161675 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
Development of a Smoking Cessation Video Series
RECRUITING · NA
-
Trauma-Informed Care for Smoking Cessation for Pregnancy
RECRUITING · NA
-
Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)
RECRUITING · NA
-
Comprehensive Tobacco Cessation for Cancer Patients and Survivors
RECRUITING · NA
-
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.